Someone whose life is saved by a new medicine is unlikely to care whether it was invented at home or on the other side of the world. Yet America’s policymakers(政策制定者) have begun treating China’s biotechnology industry as the next front(战线) in the tech war(科技战). A bill before Congress would amend(修订（法案）) the COINS Act(COINS Act 全称可能是“Crit...), which restricts American investment in sensitive technologies abroad, to include licensing(许可（技术转让）) Chinese biotech. Some want the Food and Drug Administration (FDA(FDA (Food and Drug A...)), America’s drug regulator(监管机构), to disregard(无视、不理会) clinical-trial(临床试验数据) data from China.
一个被新药拯救生命的人不太会在意这种药是在国内发明的还是在地球另一端发明的。然而，美国的政策制定者已开始将中国的生物技术产业视为科技战的新战线。国会的一项法案将修订《COINS法案》，该法案限制美国对国外敏感技术的投资，以将中国生物技术许可纳入其中。一些人希望美国药品监管机构——食品药品监督管理局（FDA）无视来自中国的临床试验数据。
America’s worries have been brought about(引起、导致) by a remarkable(显著的) shift in where innovation happens. Chinese firms ran nearly a third of the world’s clinical trials(临床试验) last year, up from just 6% a decade earlier. China is now the world’s second-largest source(来源) of new drugs, behind only America itself. In 2025 nearly half of licensing deals(许可交易) worth $50m or more were struck(达成（交易）) with Chinese firms, up from none in 2020. In some categories, such as antibody-drug conjugates(抗体药物偶联物), a promising(前景广阔的) class of cancer treatments, Chinese firms accounted for almost all the licensing.
美国的担忧源于创新发生地的显著转变。去年，中国公司进行了全球近三分之一的临床试验，而十年前仅为6%。中国现在是世界第二大新药来源国，仅次于美国。2025年，价值5000万美元及以上的许可交易中，近一半是与中国公司达成的，而2020年这一数字为零。在某些类别中，例如抗体药物偶联物（一种前景广阔的癌症治疗药物），几乎所有的许可交易都由中国公司完成。
To view Chinese medical innovation as anything other than(除了…以外的任何事物) good news would be a mistake. In AI and semiconductors, America worries about its intellectual property(知识产权) leaking(泄露) to China. In biotechnology the flow of information(信息流) runs in the opposite direction. And though anxiety about China’s dominance(主导地位) in the physical supply chain(实体供应链) for drugs is understandable—the country accounts for over 70% of the active pharmaceutical ingredients(活性药物成分) for essential drugs—manufacturing resilience(制造业韧性) and scientific collaboration are different issues. America cannot lose from(不会因…而受损) gaining new knowledge.
将中国的医疗创新视为除了好消息以外的任何事情都将是错误的。在人工智能和半导体领域，美国担心其知识产权泄露给中国。但在生物技术领域，信息流动的方向相反。尽管对中国在药品实体供应链中的主导地位感到焦虑是可以理解的——该国基本药物的活性药物成分占70%以上——但制造业韧性和科学合作是不同的问题。美国不会因获得新知识而受损。
Take the red pill
选择红色药丸